These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 28883281)

  • 41. PD-L1 and c-MET expression and survival in patients with small cell lung cancer.
    Miao L; Lu Y; Xu Y; Zhang G; Huang Z; Gong L; Fan Y
    Oncotarget; 2017 Aug; 8(33):53978-53988. PubMed ID: 28903317
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tailoring front-line therapy in diffuse large B-cell lymphoma: who should we treat differently?
    Davies A
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):284-294. PubMed ID: 29222268
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Meniscal extrusion as booster of osteoarthritis.
    Papalia R; Papalia G; Russo F; Diaz LA; Bressi F; Sterzi S; Denaro V
    J Biol Regul Homeost Agents; 2017 Dec; 31(4 Suppl 2):33-44. PubMed ID: 29202561
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacogenetics-Based Warfarin Dosing in Patients With Cardiac Valve Replacement: The Effects of CYP2C9 and VKORC1 Gene Polymorphisms.
    Farzamikia N; Sakhinia E; Afrasiabirad A
    Lab Med; 2017 Dec; 49(1):25-34. PubMed ID: 29182754
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Osteon Myospalacem Baileyi attenuates osteoclast differentiation through RANKL induced NFAT pathways.
    Cui Y; Zhao X; Mei L; Pei J; Wang S; Shao Y; Tao Y; Zhang X; Jiang L
    J Ethnopharmacol; 2018 Mar; 213():65-71. PubMed ID: 29107144
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Liver diseases: The pathogenetic role of the gut microbiome and the potential of treatment for its modulation].
    Aitbaev KA; Murkamilov IT; Fomin VV
    Ter Arkh; 2017; 89(8):120-128. PubMed ID: 28914862
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Too Many Faces of PD-L1: A Comprehensive Conformational Analysis Study.
    Ahmed M; Barakat K
    Biochemistry; 2017 Oct; 56(40):5428-5439. PubMed ID: 28898057
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers.
    Harvey JB; Phan LH; Villarreal OE; Bowser JL
    Front Immunol; 2020; 11():508. PubMed ID: 32351498
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of multiple algorithms to reliably detect structural variants in pears.
    Liu Y; Zhang M; Sun J; Chang W; Sun M; Zhang S; Wu J
    BMC Genomics; 2020 Jan; 21(1):61. PubMed ID: 31959124
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients.
    Sui X; Ma J; Han W; Wang X; Fang Y; Li D; Pan H; Zhang L
    Oncotarget; 2015 Aug; 6(23):19393-404. PubMed ID: 26305724
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers.
    Kataoka K; Shiraishi Y; Takeda Y; Sakata S; Matsumoto M; Nagano S; Maeda T; Nagata Y; Kitanaka A; Mizuno S; Tanaka H; Chiba K; Ito S; Watatani Y; Kakiuchi N; Suzuki H; Yoshizato T; Yoshida K; Sanada M; Itonaga H; Imaizumi Y; Totoki Y; Munakata W; Nakamura H; Hama N; Shide K; Kubuki Y; Hidaka T; Kameda T; Masuda K; Minato N; Kashiwase K; Izutsu K; Takaori-Kondo A; Miyazaki Y; Takahashi S; Shibata T; Kawamoto H; Akatsuka Y; Shimoda K; Takeuchi K; Seya T; Miyano S; Ogawa S
    Nature; 2016 Jun; 534(7607):402-6. PubMed ID: 27281199
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Regulatory Mechanisms of PD-L1 Expression and Its Role in Immune Evasion].
    Kataoka K
    Gan To Kagaku Ryoho; 2017 Nov; 44(11):967-971. PubMed ID: 29138368
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Genetic Alterations Involving PD-L1/PD-L2 in Human Malignancies].
    Kataoka K
    Gan To Kagaku Ryoho; 2019 May; 46(5):841-844. PubMed ID: 31189800
    [TBL] [Abstract][Full Text] [Related]  

  • 54. PD-L1-expressing extranodal diffuse large B-cell lymphoma, NOS with and without PD-L1 3'-UTR structural variations.
    Takahara T; Ishikawa E; Suzuki Y; Kogure Y; Sato A; Kataoka K; Nakamura S
    J Clin Exp Hematop; 2022 Jun; 62(2):106-113. PubMed ID: 35474033
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Novel mechanism of immune evasion in cancer via structural variations of the PD-L1 gene].
    Ogawa S
    Rinsho Ketsueki; 2017; 58(8):957-965. PubMed ID: 28883281
    [TBL] [Abstract][Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.